熱門資訊> 正文
肺部疾病治疗试验更新后，Keros取得进展
2024-09-04 03:29
- Keros Therapeutics (NASDAQ:KROS) traded higher on Tuesday after announcing that it has closed screening in its Phase 2 TROPOS trial for its lung disorder therapy cibotercept (KER-012).
- The global placebo-controlled trial is designed to evaluate cibotercept with background therapy for pulmonary arterial hypertension (PAH), a disease area served by United Therapeutics (UTHR), Johnson & Johnson (JNJ), and Merck (MRK).
- With screening for TROPOS closed, Keros (KROS) said it plans to complete enrollments by the end of September. The company is eyeing a topline data readout in Q2 2025, which, according to its CEO Jasbir Seehra, indicates an accelerated timeline.
- “The tremendous demand and speed we have observed in enrolling this trial will enable us to present topline data earlier than anticipated, now expected in the second quarter of 2025,” Seehra said.
More on Keros Therapeutics
- Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
- Keros Therapeutics appoints Jasbir S. Seehra as Chair of board
- Seeking Alpha’s Quant Rating on Keros Therapeutics
- Historical earnings data for Keros Therapeutics
- Financial information for Keros Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
